Drug Overview
Farydak (panobinostat; Novartis) is an orally available histone deacetylase (HDAC) inhibitor.
Inhibition of HDAC leads to relaxed chromatin and increased transcription, causing accumulation of proteins and cell cycle arrest or apoptosis.
In preclinical development for multiple myeloma (MM), Farydak was able to overcome resistance to traditional drugs like dexamethasone and melphalan.
The drug also demonstrated the ability to enhance the efficacy of some established MM drugs, including Velcade (bortezomib; Takeda/Johnson & Johnson).
Early-stage development sugg.that Farydak has very little effect as a monotherapy.
Farydak (panobinostat; Novartis) is an orally available histone deacetylase (HDAC) inhibitor.
Inhibition of HDAC leads to relaxed chromatin and increased transcription, causing accumulation of proteins and cell cycle arrest or apoptosis.
In preclinical development for multiple myeloma (MM), Farydak was able to overcome resistance to traditional drugs like dexamethasone and melphalan.
The drug also demonstrated the ability to enhance the efficacy of some established MM drugs, including Velcade (bortezomib; Takeda/Johnson & Johnson).
Early-stage development sugg.that Farydak has very little effect as a monotherapy.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
